Aspen’s Share Price Heals

In the wake of a turbulent earnings report that shook Aspen Pharmacare Holdings Limited (JSE: APN) back in August, the pharmaceutical powerhouse is gearing up for a potential rebound. Following a dip in profit attributable to equity holders, dwindling from R6.49 billion to R5.23 billion and leading to a shrink in earnings per share (EPS) from R14.32 to R11.77, Aspen faced a challenging market response despite a 5% revenue climb to R40.71 billion. 

Witnessing an initial 8% plunge in share price aligned with the profit decline, the company encountered a shift in trajectory. Now, a promising resurgence unfolds as the share price embarks on a path toward recovery, signalling a potentially bright horizon shaped by promising technical developments. 


The 1W chart shows a breakdown at the ascending wedge, triggered by its latest earnings report. However, since then, the price has found support at R161.56, where the potential recovery initiated, with the price recently crossing above the 50-SMA (blue line) of R170.62, signalling a bullish reversal in momentum. 

The crucial level to look out for as we advance could be the 25-SMA (green line) at R178.75. A cross above this resistance could indicate that buyers are present in the shorter term. This could catalyze some momentum toward higher resistance at R182.41 and R188.44, where a retest could occur at the wedge’s breakdown point.  

However, failure to leg above the 25-SMA resistance could indicate that the recovery could be unsustainable due to insufficient momentum. In this case, a reversion toward R167.33, the Fibonacci midpoint, could see the price fall back below the 50-SMA, with sellers potentially waiting to drive the price lower. Support at R161.56 and R159.50, the 61.8% Fibonacci golden ratio could then come into play as the pivotal support levels as we advance.  


After an 8% slump in share price following its latest earnings report, Aspen’s share price looks to recover, with a 1.5% rise week to date. The resistance at R178.74 could be crucial in the upcoming sessions to determine whether the reversal could be sustained or whether it will fade for a contraction back toward R161.56. 

Sources: Koyfin, Tradingview, Aspen Pharmacare Holdings Limited 

Piece written by Tiaan van Aswegen, Trive Financial Market Analyst 

Disclaimer: Trive South Africa (Pty) Ltd, Registration number 2005/011130/07, and an Authorised Financial Services Provider in terms of the Financial Advisory and Intermediary Services Act 2002 (FSP No. 27231). Any analysis/data/opinion contained herein are for informational purposes only and should not be considered advice or a recommendation to invest in any security. The content herein was created using proprietary strategies based on parameters that may include price, time, economic events, liquidity, risk, and macro and cyclical analysis. Securities involve a degree of risk and are volatile instruments. Market and economic conditions are subject to sudden change, which may have a material impact on the outcome of financial instruments and may not be suitable for all investors. When trading or investing in securities or alternative products, the value of the product can increase or decrease meaning your investment can increase or decrease in value. Past performance is not an indication of future performance. Trive South Africa (Pty) Ltd, and its employees assume no liability for any loss or damage (direct, indirect, consequential, or inconsequential) that may be suffered from using or relying on the information contained herein. Please consider the risks involved before you trade or invest.